| Dr Charles R Mulligan Jr, MD | |
|
4701 Ogletown Stanton Road, Helen F. Graham Cancer Center, Suite 2100, Newark, DE 19713 | |
| (302) 623-4530 | |
| (434) 200-5307 |
| Full Name | Dr Charles R Mulligan Jr |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 35 Years |
| Location | 4701 Ogletown Stanton Road, Newark, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255465571 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 15191 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christiana Hospital | Newark, DE | Hospital |
| Beebe Medical Center | Lewes, DE | Hospital |
| Union Hospital Of Cecil County | Elkton, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Christiana Care Health Services Inc | 9739097569 | 1248 |
News Archive
As high schools across the country continue to reduce physical education, recess, and athletic programs, a new study shows that regular exercise significantly reduces both suicidal thoughts and attempts among students who are bullied.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Cleaner hospitals are the top priority for Scots according to the results of a poll released by the British Medical Association (BMA), Sunday 26 June 2005. However bottom of patients' list of priorities was to have a choice for where they can have an operation.
"Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies"
› Verified 3 days ago
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770568107 PECOS PAC ID: 9739097569 Enrollment ID: O20031201000477 |
News Archive
As high schools across the country continue to reduce physical education, recess, and athletic programs, a new study shows that regular exercise significantly reduces both suicidal thoughts and attempts among students who are bullied.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Cleaner hospitals are the top priority for Scots according to the results of a poll released by the British Medical Association (BMA), Sunday 26 June 2005. However bottom of patients' list of priorities was to have a choice for where they can have an operation.
"Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies"
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles R Mulligan Jr, MD 200 Hygeia Dr, Suite 2300, Newark, DE 19713-2049 Ph: (434) 200-3100 | Dr Charles R Mulligan Jr, MD 4701 Ogletown Stanton Road, Helen F. Graham Cancer Center, Suite 2100, Newark, DE 19713 Ph: (302) 623-4530 |
News Archive
As high schools across the country continue to reduce physical education, recess, and athletic programs, a new study shows that regular exercise significantly reduces both suicidal thoughts and attempts among students who are bullied.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Cleaner hospitals are the top priority for Scots according to the results of a poll released by the British Medical Association (BMA), Sunday 26 June 2005. However bottom of patients' list of priorities was to have a choice for where they can have an operation.
"Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies"
› Verified 3 days ago
Dr. Ray A Blackwell, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Suite 1e50, Newark, DE 19718 Phone: 302-733-1980 Fax: 302-733-1986 | |
Dr. Ahmad Aftab Khan, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd Ste 1e50, Newark, DE 19718 Phone: 302-733-1980 Fax: 302-733-1986 | |
Dr. Katrhleen Winifred Mcnicholas, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 4755 Ogletown Stanton Rd, 1e50, Newark, DE 19718 Phone: 302-733-1980 Fax: 302-733-1986 | |
Thomas L Bauer, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 4701 Ogletown Stanton Rd, Helen F. Graham Cancer Center, Suite 2100, Newark, DE 19713 Phone: 302-623-4530 Fax: 302-623-4578 | |
D Bruce Panasuk, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 4701 Ogletown-stanton Road, Suite 1204, Newark, DE 19713 Phone: 302-623-4530 | |
Chandra Shekhar R Beesam, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 4735 Ogletown Stanton Rd, Map 2, Suite 1201& 1205, Newark, DE 19713 Phone: 302-733-1980 Fax: 302-733-1986 |